%0 Journal Article
%T Prevalence of SARS-CoV-2-specific antibodies in a sample of the Lithuanian population-based study in Spring 2023.
%A Simanavičius M
%A Kučinskaitė-Kodzė I
%A Kaselienė S
%A Sauliūnė S
%A Gudas D
%A Jančorienė L
%A Jasinskienė R
%A Vitkauskienė A
%A Žūtautienė R
%A Žvirblienė A
%A Stankūnas M
%J Heliyon
%V 10
%N 8
%D 2024 Apr 30
%M 38681561
%F 3.776
%R 10.1016/j.heliyon.2024.e29343
%X <B>UNASSIGNED: </B>Despite positive trends in SARS-CoV-2 epidemiology, seroprevalence surveys remain an important tool for estimating the magnitude of the COVID-19 pandemic. This study aimed to investigate the prevalence of IgG antibodies against SARS-CoV-2 nucleocapsid (N) and spike (S) proteins in a sample of the Lithuanian population (N = 517) and evaluate how the pattern of seropositivity correlates with the levels of SARS-CoV-2 infection and vaccination.<BR><B>UNASSIGNED: </B>Study participants (aged 18-88 years) filled in the questionnaire self-reporting their demographic-social variables, health status, and SARS-CoV-2-related status. The anti-S and anti-N IgG levels were estimated using a microarray ELISA test.<BR><B>UNASSIGNED: </B>After several pandemic waves and vaccination campaign, the seroprevalence of SARS-CoV-2-specific IgG in the analyzed sample was 97.87 % by March-May 2023. We determined the 96.91 % prevalence of anti-S and 58.03 % prevalence of anti-N IgG. The majority of study participants (71.18 %) had hybrid immunity induced by vaccination and SARS-CoV-2 infection. 20.3 % of study participants were anti-N IgG positive without reporting any previous symptoms or a positive SARS-CoV-2 test. A decline of anti-N IgG positivity within 9 months after infection was observed.<BR><B>UNASSIGNED: </B>This study demonstrates high total seroprevalence in March-May 2023 in all age groups indicating a widely established humoral immunity against SARS-CoV-2 in Lithuania.